Therapeutic potential of cysteine-rich protein 61 in rheumatoid arthritis

Gene. 2016 Oct 30;592(1):179-185. doi: 10.1016/j.gene.2016.07.053. Epub 2016 Jul 25.

Abstract

Cysteine-rich protein 61 (Cyr61)/CCN1, a product of an immediate early gene, can directly accommodate cell adhesion and migratory processes whilst simultaneously regulating the production of other cytokines and chemokines through paracrine and autocrine feedback loops. This intricate functionality of Cyr61 indicate its important role in targeting components of the infectious or chronic inflammatory disease processes including rheumatoid arthritis (RA). Recent work has focused on the role of Cyr61 in RA. For example, Cyr61 induced proIL-1β production in FLS via the AKT-dependent NF-κB signaling pathway. Moreover, Cyr61-siRNA decreased the levels of matrix metalloproteinase (MMP)-3 and MMP-13, and induced apoptosis in RA-FLS cells. These results indicated that Cyr61 may represent a novel target for the treatment of RA. In this article we will introduce the molecular properties of Cyr61, discuss the function of Cyr61, and the therapeutic potential of modulating the Cyr61 in RA.

Keywords: Akt; CCN; Cyr61; Rheumatoid arthritis.

Publication types

  • Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / metabolism*
  • Arthritis, Rheumatoid / therapy
  • Cysteine-Rich Protein 61 / antagonists & inhibitors
  • Cysteine-Rich Protein 61 / immunology
  • Cysteine-Rich Protein 61 / metabolism*
  • Humans
  • Immunotherapy
  • Molecular Targeted Therapy
  • Signal Transduction

Substances

  • CCN1 protein, human
  • Cysteine-Rich Protein 61